Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Djordje Atanackovic, Mary Steinbach, Sabarinath Venniyil Radhakrishnan & Tim Luetkens. (2016) Immunotherapies targeting CD38 in Multiple Myeloma. OncoImmunology 5:11.
Read now
Read now
Articles from other publishers (31)
Leena Gupta, Pratibha Suku, Aishwarya Dash, Parveen Bose, Praveen Sharma, Nabhajit Mallik, Sreejesh Sreedharanunni, Neelam Varma, Aditya Jandial, Pankaj Malhotra & Man Updesh Singh Sachdeva. (2024) Detection of circulating normal and tumor plasma cells in newly diagnosed patients of multiple myeloma and their associations with clinical and laboratory parameters. Current Problems in Cancer 48, pages 101025.
Crossref
Crossref
Ritu Gupta, Dragan Jevremovic, Smith J. Mathew & Shaji Kumar. (2023) Multi-parametric flow cytometry in the evaluation of plasma cell proliferative disorders- Current paradigms for clinical practice. Clinical Lymphoma Myeloma and Leukemia.
Crossref
Crossref
Yuan Xia, Na Shen, Run Zhang, Yujie Wu, Qinglin Shi, Jianyong Li, Lijuan Chen, Min Xu & Yuanyuan Jin. (2023) High-risk multiple myeloma predicted by circulating plasma cells and its genetic characteristics. Frontiers in Oncology 13.
Crossref
Crossref
Luca Bertamini, Stefania Oliva, Delia Rota-Scalabrini, Laura Paris, Sonia Morè, Paolo Corradini, Antonio Ledda, Massimo Gentile, Giovanni De Sabbata, Giuseppe Pietrantuono, Anna Pascarella, Patrizia Tosi, Paola Curci, Milena Gilestro, Andrea Capra, Piero Galieni, Francesco Pisani, Ombretta Annibali, Federico Monaco, Anna Marina Liberati, Salvatore Palmieri, Mario Luppi, Renato Zambello, Francesca Fazio, Angelo Belotti, Paola Tacchetti, Pellegrino Musto, Mario Boccadoro & Francesca Gay. (2022) High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology 40:27, pages 3120-3131.
Crossref
Crossref
Mantas Radzevičius, Vaidas Dirsė, Indrė Klimienė, Rėda Matuzevičienė, Zita Aušrelė Kučinskienė & Valdas Pečeliūnas. (2022) Multiple Myeloma Immunophenotype Related to Chromosomal Abnormalities Used in Risk Assessment. Diagnostics 12:9, pages 2049.
Crossref
Crossref
Shaji Kumar, Lawrence Baizer, Natalie S. Callander, Sergio A. Giralt, Jens Hillengass, Boris Freidlin, Antje Hoering, Paul G. Richardson, Elena I. Schwartz, Anthony Reiman, Suzanne Lentzsch, Philip L. McCarthy, Sundar Jagannath, Andrew J. Yee, Richard F. Little & Noopur S. Raje. (2022) Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee. Blood Cancer Journal 12:6.
Crossref
Crossref
Dongfang Ouyang, Hanqing Zhang, Bin Tang, Jaewon Park, Lina Hu, Jenny Hirst, Lidan You & Yonghua Li. (2022) Clinical Significance of Circulating Clonal Plasma Cells Detected by a Novel Microfluidic Chip in Multiple Myeloma. Journal of Biomedical Nanotechnology 18:6, pages 1630-1639.
Crossref
Crossref
Guldane Cengiz Seval & Meral Beksac. (2022) Is Quantification of Measurable Clonal Plasma Cells in Stem Cell Grafts (gMRD) Clinically Meaningful?. Frontiers in Oncology 12.
Crossref
Crossref
Emilie Arnault Carneiro, Filipa Barahona, Carolina Pestana & Cristina João. (2022) Is Circulating DNA and Tumor Cells in Myeloma the Way Forward?. Hemato 3:1, pages 63-81.
Crossref
Crossref
Amro M. Soliman, Srijit Das & Seong Lin Teoh. (2021) Next-Generation Biomarkers in Multiple Myeloma: Understanding the Molecular Basis for Potential Use in Diagnosis and Prognosis. International Journal of Molecular Sciences 22:14, pages 7470.
Crossref
Crossref
Indrė Klimienė, Mantas Radzevičius, Rėda Matuzevičienė, Katažina Sinkevič‐Belliot, Zita Aušrelė Kučinskienė & Valdas Pečeliūnas. (2020) Adhesion molecule immunophenotype of bone marrow multiple myeloma plasma cells impacts the presence of malignant circulating plasma cells in peripheral blood. International Journal of Laboratory Hematology 43:3, pages 403-408.
Crossref
Crossref
Mara N. Zeissig, Andrew C. W. Zannettino & Kate Vandyke. (2020) Tumour Dissemination in Multiple Myeloma Disease Progression and Relapse: A Potential Therapeutic Target in High-Risk Myeloma. Cancers 12:12, pages 3643.
Crossref
Crossref
Mara N. Zeissig, Duncan R. Hewett, Vasilios Panagopoulos, Krzysztof M. Mrozik, L. Bik To, Peter I. Croucher, Andrew C.W. Zannettino & Kate Vandyke. (2020) Expression of the chemokine receptor CCR1 promotes the dissemination of multiple myeloma plasma cells <i>in vivo</i>. Haematologica 106:12, pages 3176-3187.
Crossref
Crossref
Juan-José Garcés, Gabriel Bretones, Leire Burgos, Rafael Valdes-Mas, Noemi Puig, Maria-Teresa Cedena, Diego Alignani, Idoia Rodriguez, Diana Álvarez Puente, Miguel-García Álvarez, Ibai Goicoechea, Sara Rodriguez, Maria-Jose Calasanz, Xabier Agirre, Juan Flores-Montero, Luzalba Sanoja-Flores, Paula Rodriguez-Otero, Rafael Rios, Joaquin Martinez-Lopez, Pamela Millacoy, Luis Palomera, Rafael Del Orbe, Albert Pérez-Montaña, Halima El Omri, Felipe Prosper, Maria-Victoria Mateos, Laura Rosiñol, Joan Blade, Juan-Jose Lahuerta, Alberto Orfao, Carlos Lopez-Otin, Jesus F. San Miguel & Bruno Paiva. (2020) Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma. Leukemia 34:11, pages 3007-3018.
Crossref
Crossref
Shuang Geng, Jing Wang, Xiannian Zhang, Jia‐jia Zhang, Fan Wu, Yuhong Pang, Yuping Zhong, Jianbin Wang, Wenming Wang, Xiaoqing Lyu, Yanyi Huang & Hongmei Jing. (2019) Single‐cell RNA sequencing reveals chemokine self‐feeding of myeloma cells promotes extramedullary metastasis. FEBS Letters 594:3, pages 452-465.
Crossref
Crossref
Ningning Wang, Nahom Tesfaluul, Jia Li, Xiaojuan Gao, Shuai Liu & Baohong Yue. (2019) Enrichment of circulating myeloma cells by immunomagnetic beads combined with flow cytometry for monitoring minimal residual disease and relapse in patients with multiple myeloma. Annals of Hematology 98:12, pages 2769-2780.
Crossref
Crossref
Adam Levin, Parameswaran Hari & Binod Dhakal. (2018) Novel biomarkers in multiple myeloma. Translational Research 201, pages 49-59.
Crossref
Crossref
Prashant R. Tembhare, Sitaram Ghogale, Wilma Tauro, Yajamanam Badrinath, Nilesh Deshpande, Shweta Kedia, Keziah Cherian, Nikhil V. Patkar, Gaurav Chatterjee, Sumeet Gujral & Papagudi G. Subramanian. (2018) Evaluation of CD229 as a new alternative plasma cell gating marker in the flow cytometric immunophenotyping of monoclonal gammopathies. Cytometry Part B: Clinical Cytometry 94:3, pages 509-519.
Crossref
Crossref
A Besse, S C Stolze, L Rasche, N Weinhold, G J Morgan, M Kraus, J Bader, H S Overkleeft, L Besse & C Driessen. (2017) Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma. Leukemia 32:2, pages 391-401.
Crossref
Crossref
Brad Foulk, Mike Schaffer, Steve Gross, Chandra Rao, Denis Smirnov, Mark C. Connelly, Shalini Chaturvedi, Manjula Reddy, Greg Brittingham, Marielena Mata, Madeline Repollet, Claudia Rojas, Daniel Auclair, Mary DeRome, Brendan Weiss & Amy K. Sasser. (2018) Enumeration and characterization of circulating multiple myeloma cells in patients with plasma cell disorders. British Journal of Haematology 180:1, pages 71-81.
Crossref
Crossref
T Jelinek, R Bezdekova, M Zatopkova, L Burgos, M Simicek, T Sevcikova, B Paiva & R Hajek. (2017) Current applications of multiparameter flow cytometry in plasma cell disorders. Blood Cancer Journal 7:10, pages e617-e617.
Crossref
Crossref
Gaurav Chatterjee, Sumeet Gujral, Papagudi G. Subramanian & Prashant R. Tembhare. (2017) Clinical Relevance of Multicolour Flow Cytometry in Plasma Cell Disorders. Indian Journal of Hematology and Blood Transfusion 33:3, pages 303-315.
Crossref
Crossref
M Espiño, A Arteche-López, S Medina, C Muñoz-Calleja, M J Blanchard, A Alegre, F J López-Jiménez & L M Villar. (2017) Involved/uninvolved heavy/light chain index can predict progression in transplanted multiple myeloma patients. Bone Marrow Transplantation 52:8, pages 1206-1207.
Crossref
Crossref
Jia Li, Ningning Wang, Nahom Tesfaluul, Xiaojuan Gao, Shuai Liu & Baohong Yue. (2017) Prognostic value of circulating plasma cells in patients with multiple myeloma: A meta-analysis. PLOS ONE 12:7, pages e0181447.
Crossref
Crossref
R Chakraborty, E Muchtar, S K Kumar, D Jevremovic, F K Buadi, D Dingli, A Dispenzieri, S R Hayman, W J Hogan, P Kapoor, M Q Lacy, N Leung & M A Gertz. (2016) Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era. Blood Cancer Journal 6:12, pages e512-e512.
Crossref
Crossref
Barbara Muz, Pilar de la Puente, Feda Azab, Micah John Luderer, Justin King, Ravi Vij & Abdel Kareem Azab. (2016) A CD138-independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma. British Journal of Haematology 173:1, pages 70-81.
Crossref
Crossref
Scott Ely, Noa Biran & Ajai Chari. (2014) What We Mean When We Talk About MRD in Myeloma. A Review of Current Methods. Part 1 of a Two-Part Series. Current Hematologic Malignancy Reports 9:4, pages 379-388.
Crossref
Crossref
Noa Biran, Scott Ely & Ajai Chari. (2014) Controversies in the Assessment of Minimal Residual Disease in Multiple Myeloma: Clinical Significance of Minimal Residual Disease Negativity Using Highly Sensitive Techniques. Current Hematologic Malignancy Reports 9:4, pages 368-378.
Crossref
Crossref
Bruno PaivaTeresa Paino, Jose-Maria Sayagues, Mercedes Garayoa, Laura San-Segundo, Montserrat Martín, Ines Mota, María-Luz Sanchez, Paloma Bárcena, Irene Aires-Mejia, Luis Corchete, Cristina Jimenez, Ramon Garcia-Sanz, Norma C. Gutierrez, Enrique M. Ocio, Maria-Victoria Mateos, Maria-Belen Vidriales, Alberto Orfao & Jesús F. San Miguel. (2013) Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile. Blood 122:22, pages 3591-3598.
Crossref
Crossref
H A F Stessman, A Mansoor, F Zhan, S Janz, M A Linden, L B Baughn & B Van Ness. (2013) Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib. Leukemia 27:10, pages 2075-2077.
Crossref
Crossref
Kyle J Thulien, Andrew R Belch, Tony Reiman & Linda M Pilarski. (2012) In non-transplant patients with multiple myeloma, the pre-treatment level of clonotypic cells predicts event-free survival. Molecular Cancer 11:1.
Crossref
Crossref